Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 395-407 , September 2009

Advances in the biology and therapy of patients with chronic myeloid leukaemia

  • Elias Jabbour, MD (Assistant Professor)

      Affiliations

    • Department of Leukemia, The University of Texas, Unit 428, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 713 792 7305; Fax: +1 713 794 4997.
    • ,
  • Carmen Fava, MD (Professor)

      Affiliations

    • Division of Haematology and Internal Medicine, Department of Biological Sciences of the University of Turin, Turin, Italy
    • ,
  • Hagop Kantarjian, MD (Professor)

      Affiliations

    • Department of Leukemia, The University of Texas, Unit 428, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA

References 

  1. Mughal TI, Goldman JM. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?. Front Biosci. 2006;11:198–208
  2. Hill JM, Meehan KR. Chronic myelogenous leukemia. Curable with early diagnosis and treatment. Postgrad Med. 1999;106:149–152157–159
  3. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207–219
  4. Pasternak G, Hochhaus A, Schultheis B, et al. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol. 1998;124:643–660
  5. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293
  6. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–3356
  7. Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. Blastic transformation of p53-deficient bone marrow cells by p2lObcr/abl tyrosine kinase. Proc Natl Acad Sci USA. 1996;93:13137–13142
  8. Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:2737
  9. Beck Z, Kiss A, Tóth FD, et al. Alterations ofP53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma. 2000;38:587–597
  10. Sherr C, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103–112
  11. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566
  12. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330–1340
  13. Sessions J. Chronic myeloid leukemia in 2007. J Manag Care Pharm. 2007;13:4–7
  14. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004
  15. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–2541
  16. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542–2551
  17. National Comprehensive Cancer Network . NCCN: clinical practice guidelines in oncology. Chronic Myelogenous Leuk. 2009;Version 1 www.nccn.org/index.asp
  18. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820
  19. O'Brien SG, Guilhot F, Goldman JM, et al. International randomized study of Interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood. 2008;112:76
  20. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018–1029
  21. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767–1773
  22. Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16:122–1231
  23. Hamdan MY, Sanders L, Oliveria S, et al. Discontinuation and dose modification of imatinib in clinical practice. J Clin Oncol. 2007;25:7045
  24. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008;112:2112–2118
  25. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors – review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37
  26. Jabbour E, Cortes J, O'Brien S, et al. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma. 2007;7:S51–S57
  27. Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009;115:551–560
  28. Jabbour E, Kantarjian H, O'Brien S, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood. 2008;113:2154–2160
  29. Sprycel (dasatinib) [package insert]. 2007.
  30. Dasatinib prescribing information, May 2008.
  31. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303–2309
  32. Cervantes F, Baccarani M, Lipton J, et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: A two-year update of the START-C study. Haematologica. 2008;93:372
  33. Rousselot P, Corm S, Paquette R, et al. Dasatinib compared with high-dose imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) after failure of standard-dose imatinib – A two-year update of the START-R study. Haematologica. 2008;93:48
  34. Shah NP, Kim DW, Kantarjian HM, et al. Dasatinib 50mg or 70mg BID compared to 100mg or 140mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034. J Clin Oncol. 2007;25:358
  35. Tasigna (nilotinib) [package insert]. 2007.
  36. Kantarjian HM, Giles F, Bhalla KN, et al. Nilotinib in Chronic Myeloid Leukemia Patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood. 2008;112:1112
  37. Jabbour E, Kantarjian HM, Baccarani M, et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP). Blood. 2008;112:1103
  38. Cortes JE, Baccarani M, Guilhot F, et al. A Phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study. Blood. 2008;112:130–131
  39. Baccarani M, Castagnetti F, Simonsson B, et al. Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): Results of an European LeukemiaNet prospective study comparing 400 mg and 800 mg front-line. Blood. 2008;112:75
  40. Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood. 2008;112:170
  41. Rosti G, Castagnetti F, Poerio A, et al. High and early rates of cytogenetic and molecular response with nilotinib 800mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: Results of a phase 2 trial of the GIMEMA CML Working Party. Blood. 2008;112:73–74
  42. Cortes J, O'Brien S, Borthakur G, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood. 2008;112:74
  43. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63:375–381
  44. Cortes J, Kantarjian HM, Kim DW, et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. Blood. 2008;112:1098
  45. Craig AR, Kantarjian HM, Cortes JE, et al. phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J Clin Oncol. 2007;25:368s;(abstract # 7046)
  46. Cortes J, Paquette R, Talpaz M, et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF- 1R/aurora kinase inhibitor XL228 in patients with Ph++Leukemias with either failure to multiple TKI therapies or with T315I mutation. Blood. 2008;112:3232
  47. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  48. Rahmani M, Nguyen TK, Dent P, et al. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol. 2007;72:788–795
  49. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008;111:4355–4364
  50. Paquette RL, Shah NP, Sawyers CL, et al. PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. [abstract] Blood. 2007;110:1030
  51. Revill P, Mealy N, Serradell N, et al. Panobinostat. Histone deacetylase (HDAC) inhibitor, apoptosis inducer, oncolytic. Drugs Future. 2007;32:315–322
  52. Spencer A, Prince M, DeAngelo DJ, et al. Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies. [abstract] Blood. 2007;110:907
  53. Dai Y, Chen S, Venditti CA, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate. [abstract] Blood. 2007;110:1041a
  54. Fiskus W, Pranpat M, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells. Blood. 2006;108:645–652
  55. Dasmahapatra G, Yerram N, Dai Y, et al. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res. 2007;13:4280–4290
  56. Kadia TM, Borthakur G, Wierda W, et al. A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia. [abstract] J Clin Oncol. 2007;25(18S):7066
  57. O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002;94:2024–2032
  58. O'Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003;98:888–893
  59. Cortes , Khoury HJ, Corm S, et al. Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation. [abstract] J Clin Oncol. 2008;26:7021
  60. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657–662
  61. Kantarjian HM, O'Brien S, Cortes J, et al. Results of decitabine (5′-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98:522–528
  62. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948–3956
  63. Guilhot F, Mahon F-X, Guilhot J, et al. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC). Blood (ASH Annual Meeting Abstracts). Nov 2008;112:183
  64. Hehlmann R, Saussele S, Lauseker M, et al. Randomized clinical trial for the optimization of imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV. Haematologica. 2009;94(Suppl. 2):193;abs. 0478
  65. Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3500–3507
  66. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007 Feb 15;109(4):1782–1789
  67. Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: high survival rate following allogeneic HSCT after imatinib failure: results of the german CML study IV. Blood (ASH Annual Meeting Abstracts). Nov 2008;112:448
  68. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108:1421–1423
  69. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110:4005–4011
  70. Muller MC, Cortes J, Kim DW, et al. Dasatinib efficacy in patients with chronic myelogenous leukemia in chronic phase (CML-CP) and pre-existing BCR-ABL mutations. Blood. 2008;112:abstract 449
  71. Hughes T, Saglio G, Branford S, et al. Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP). J Clin Oncol. 2009;27(25):4204–4210
  72. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008;112:53–55
  73. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:7374–7379
  74. Jabbour E, kantarjian HM, Jones D, et al. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008;112:4839–4842

PII: S1521-6926(09)00066-8

doi: 10.1016/j.beha.2009.09.002

Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 395-407 , September 2009

Article Tools